You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Pfizer’s Lorbrena scores US priority review

Pfizer’s tyrosine kinase inhibitor (TKI) Lorbrena (lorlatinib) has scored a US Food and Drug Administration (FDA) priority review for the first-line treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).